ideasIdea
Fund scalp cooling and hair-preserving measures for every alopecia-inducing regimen
Losing hair is one of the most distressing side-effects of chemotherapy and can often be prevented with a cooling cap. Make it routinely available and paid for.
Scalp cooling reduces chemotherapy-induced alopecia in randomised trials and is cleared by regulators, yet availability depends on charity, geography and unit culture. The proposal is payer coverage and unit-level capacity for scalp cooling for all patients receiving alopecia-inducing regimens who want it, plus trials of adjunctive topical agents, with hair preservation and body-image outcomes measured in registries.
Hypothesis
Universal availability raises use to over half of eligible patients and reduces refusal of alopecia-inducing regimens and treatment-related distress.
Rationale
Alopecia influences treatment choice and self-image; the intervention exists and is safe, and the barrier is purely organisational and financial.
What would test it
Payer covers scalp cooling in one region; measure uptake, hair preservation rates and refusal of recommended chemotherapy versus a matched region.
Maturity
being tested at scale
Who has to act
payer
Cost to try
Small (under $1M)
Years to first evidence
2
Bottlenecks it attacks
- Toxicity and quality of life are undervalued · Trials measure how long people live, not how they live. Side-effects are under-reported and under-treated.